US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
News headline image
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 6 7 Next >